Media Advisory: New Investigational Cancer Vaccine to be Announced by RPCI at Press Conference Tuesday

Friday, January 20, 2012

WHAT:    International press conference announcing development of an investigational vaccine, to be produced through a process available only at Roswell Park Cancer Institute (RPCI), that has the potential to eradicate cancer cells and prevent disease relapse.

WHEN:   TUESDAY, January 24, 10 a.m. EST
Live stream of press conference will be available at http://www.roswellpark.org

WHERE:  Zebro Conference Room, Roswell Park Cancer Institute Center for Genetics & Pharmacology, 645 Virginia Street near Ellicott Street, Buffalo, NY

NOTES:   Join Dr. Donald L. Trump, President and CEO of Roswell Park Cancer Institute (RPCI), Dr. Kunle Odunsi, Director of RPCI’s Center for Immunotherapy, and Dr. Christopher Choi, Director of the Institute’s Therapeutic Cell Production Facility, for this announcement of U.S. Food and Drug Administration (FDA) approval for an investigational cancer therapy to be produced at RPCI for clinical study.

Cancer patients who would like to know more about this clinical research study may call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

-30-

Media Contact: 

Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org